Center for Health Policy Science & Tobacco Research, RTI International, 3040 E. Cornwallis Rd., Research Triangle Park, NC, USA.
Center for Health Policy Science & Tobacco Research, RTI International, 3040 E. Cornwallis Rd., Research Triangle Park, NC, USA.
Drug Alcohol Depend. 2020 Dec 1;217:108275. doi: 10.1016/j.drugalcdep.2020.108275. Epub 2020 Sep 9.
Cannabis warning labels can communicate risks, but there is little research on warning perceptions and differences by product type.
In a 2019 online survey, 1,000 U.S. adults (500 cannabis users and 500 cannabis non-users who used tobacco) were randomly assigned to view no warning or one of four U.S. or Canadian warnings displayed on images of packaging for dried flower or edible cannabis. The warnings described cannabis risks related to psychosis, addiction, lack of FDA oversight, and impaired driving. We used linear regression to examine perceptions of warnings and product harm as a function of product type (dried or edible) and warning. We examined which warning participants selected as most effective for discouraging youth use and impaired driving.
Participants found the addiction warning (cannabis users: B = -1.04, p < 0.001; cannabis non-users: B = 1.17, p < 0.001) and psychosis warning (users: B = -0.65, p < 0.05; non-users: B = -0.71, p < 0.05) less believable than the driving warning but indicated that they learned more from the psychosis warning than the driving warning (users: B = 0.88, p < 0.01; non-users (B = 1.60, p < 0.001). Participants viewing any warning considered smoking cannabis to be more harmful than those viewing no warning (all p < 0.05). The psychosis warning was most frequently selected as the best warning for discouraging youth use.
Warnings have the potential to educate consumers and impact cannabis harm perceptions. Warnings have similar effects across product types, potentially eliminating the need for product type-specific warnings. The association of cannabis use with risk for psychosis, a topic addressed in Canadian warnings, could be a useful topic of focus in U.S. warnings.
大麻警示标签可以传达风险,但关于警示认知及其按产品类型划分的差异的研究甚少。
在 2019 年的一项在线调查中,1000 名美国成年人(500 名大麻使用者和 500 名使用烟草的大麻非使用者)被随机分配观看无警示或四种美国或加拿大警示中的一种,这些警示显示在干花或食用大麻包装图像上。这些警示描述了与精神病、成瘾、缺乏 FDA 监管和驾驶障碍相关的大麻风险。我们使用线性回归来检验对警示和产品危害的认知,其作用因素为产品类型(干制品或食用品)和警示。我们还检验了参与者认为哪种警示最能有效劝阻年轻人使用和减少驾驶障碍。
参与者发现成瘾警示(大麻使用者:B = -1.04,p < 0.001;大麻非使用者:B = 1.17,p < 0.001)和精神病警示(使用者:B = -0.65,p < 0.05;非使用者:B = -0.71,p < 0.05)不如驾驶障碍警示可信,但表示他们从精神病警示中学到的比从驾驶障碍警示中学到的多(使用者:B = 0.88,p < 0.01;非使用者:B = 1.60,p < 0.001)。观看任何警示的参与者认为吸食大麻比不观看警示的参与者更有害(所有 p < 0.05)。精神病警示最常被选为劝阻年轻人使用的最佳警示。
警示有潜力教育消费者并影响大麻危害认知。警示在产品类型方面具有相似的效果,可能消除了针对特定产品类型的警示的必要性。将大麻使用与精神病风险联系起来,这是加拿大警示中涉及的一个主题,可能是美国警示的一个有用的重点主题。